Work

Supplementary Figure 7 from Targeting Menin in T-lineage Acute Lymphoblastic Leukemia

Year: 2026

Type: supplementary-materials

Abstract: (A) Immunoblots confirming MEF2C overexpression in MOLT4 cells. (B) Eight-day growth curves for control vs MEF2C OE MOLT4 cells. (C) Co-treatment with ziftomenib (0.3 µM) and CDK1/2 inhibitor (0.3 µM) in control vs MEF2C OE MOLT4 cells.

DOI: 10.1158/1535-7163.33151979

Authors: Kathryn Shimamoto, Diren Arda Karaoglu, Olivia Arnold, Arjun Dhar, Zachary Chan, Giorgia Giordano, Jason X. Cheng, Hamed R. Youshanlouei, Anand A. Patel, Adam S. DuVall, Michael W. Drazer, Linda Kessler, Francis Burrows, Olatoyosi Odenike, Michael J. Thirman, Wendy Stock, Caner Saygin

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7172444996

Cites:

Cited by:

Related to: 10